This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients(n=689) who underwent successful stenting were randomly assigned to receive cilostazol(group 1, n=344, 612 les...This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients(n=689) who underwent successful stenting were randomly assigned to receive cilostazol(group 1, n=344, 612 lesions) or clopidogrel(group 2, n=345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days(2.6%in group 1 vs 2.0%in group 2, p=0.61) and side effects that required cessation of study drug(0.6%each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.展开更多
文摘This study compared the safety and efficacy of cilostazol and clopidogrel after coronary stenting. Patients(n=689) who underwent successful stenting were randomly assigned to receive cilostazol(group 1, n=344, 612 lesions) or clopidogrel(group 2, n=345, 628 lesions). The incidence of subacute stent thrombosis or major adverse cardiac events, including death, myocardial infarction, and target lesion revascularization within 30 days(2.6%in group 1 vs 2.0%in group 2, p=0.61) and side effects that required cessation of study drug(0.6%each) did not differ statistically between groups. These results indicate that cilostazol is as safe and effective as clopidogrel in preventing thrombotic complications after stenting.
